Contact this trialFirst, we need to learn more about you.
Protein Kinase Inhibitor
RP-3500 + PARP Inhibitors for Advanced Cancer
Recruiting1 awardPhase 1 & 2
Rochester, Minnesota
This trial is testing the safety and effectiveness of two drugs, Niraparib or Olaparib, when used with RP-3500 to treat advanced solid tumors. The goal is to find the maximum tolerated dose of RP-3500 and to see if the combination has any anti-tumor activity.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.